Immune-based strategies for treatment and prevention of hepatitis C virus infection

  • Fatma Abdelaziz Amer Zagzig University
  • Marwa Abdelazim Mansour Zagazig Faculty of Medicine
  • Shyma Abdelazim Mansour Zagazig Faculty of Medicine

Abstract

Hepatitis C virus (HCV) infection affects about 3% of the world’s population. Currently, the gold standard therapy does not work in a high percentage of patients and with all genotypes. In addition, it is costly, is associated with many side-effects. So, more convenient therapeutic strategies have been sought. These include, direct acting antivirals (DAAs), and immune-based therapy. Four DAA molecules have recently been approved by FDA.  Immune-based therapy aims at augmenting host immunity, thus prevention of infection or clearance of the virus with subsequent recovery can occur. Boosting T cell responses and activating humoral immune reactions have been targeted in the development of novel combating tools. The most intensively studied immune-therapeutic strategies are: 1) vaccines; either therapeutic or prophylactic, 2) dendritic cell immunotherapy, 3) antagonists of T cell inhibitory factors, 4) anti-HCV neutralizing antibodies, 4) cytokines and chemokines, 5) agonists for TLRs, and 6) caspase inhibitors.

Published
Jul 28, 2014
How to Cite
AMER, Fatma Abdelaziz; MANSOUR, Marwa Abdelazim; MANSOUR, Shyma Abdelazim. Immune-based strategies for treatment and prevention of hepatitis C virus infection. The International Arabic Journal of Antimicrobial Agents, [S.l.], v. 4, n. 1, july 2014. ISSN 2174-9094. Available at: <http://imed.pub/ojs/index.php/IAJAA/article/view/870>. Date accessed: 19 nov. 2019.
Section
Articles

Keywords

HCV immune response, vaccine, dendritic cells, neutralizing antibodies, T cells inhibitors, cytokines, caspases, Toll-like receptors